- Home
- PIII vs NCNA Comparison
PIII vs NCNA Comparison
Compare PIII & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | NCNA |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 8.8M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | PIII | NCNA |
|---|---|---|
| Price | $2.14 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | ★ 111.2K | 49.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $0.03 |
| 52 Week High | $11.30 | $10.00 |
Technical Indicators
Market Signals| Indicator | PIII | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 32.14 |
| Support Level | $1.96 | $2.00 |
| Resistance Level | $2.85 | $2.19 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 46.24 | 22.39 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.